GenSight Biologics S.A.

Registration Form • Apr 8, 2021

GenSight Biologics Announces the Filing of its 2020 Universal Registration Document

Paris, France, April 8, 2021, 7.00 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2020 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.21-0276.

The universal registration document notably includes:

• the 2020 annual financial report;
• the management report;
• the report on corporate governance; and
• the description of the share buyback program.

This universal registration document may be consulted on the Company's website (www.gensightbiologics.com), "Investors" section, and on the AMF's website (www.amf-france.org).

Contacts

GenSight Biologics

Chief Financial Officer Thomas Gidoin tgidoin@gensight-biologics.com +33 (0)1 76 21 72 20

LifeSci Advisors

Investor Relations Guillaume van Renterghem gvanrenterghem@lifesciadvisors.com +41 (0)76 735 01 31

RooneyPartners

Media Relations Marion Janic mjanic@rooneyco.com +1-646-537-5649

Orpheon Finance

Retail Investors James Palmer j.palmer@orpheonfinance.com +33 (0)7 60 92 77 74

About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics' lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.